![\"click](\"https:\/\/www.bumc.bu.edu\/cardiovascularproteomics\/files\/Images\/miniPubsUNESCOwebsite.jpg\")
<\/a>Click the publications icon at right to read these articles:<\/p>\nIn project 8, significant progress in the elucidation of a novel cytokine-endothelial cell\/EPC regulatory axis has been made. Researchers have found that the fat-derived hormone, adiponectin, is a regulator of EPC mobilization and endothelial function. Adiponectin is down-regulated in cardiovascular disorders, perhaps explaining the diminished EPC responses in patients and animal models, hypothesize the researchers. In addition, the group is exploring the role of reactive oxygen species in EPC mobilization and phenotype, demonstrating that GPX-deficient mice display impaired angiogenesis in response to hindlimb ischemia and a marked reduction in EPC mobilization in response to this injury. A methods advance developed in the project concerns procedures for the identification of novel endothelial\/EPC-regulatory proteins.<\/p>\n
Project 8 investigators have established procedures for the isolation and characterization of progenitor cells from animal (bone marrow and circulating) and patient sources (circulating). They have learned how to identify these cell types by the analysis of marker proteins and by conducting studies that examine how animal and patient EPC phenotypes change over time in culture. A series of DNA microarray analyses have been performed and a series of programs to assess functional relationships between the regulated proteins employed.<\/p>\n
<\/a>Click the publications icon at right to read these articles:<\/p>\n
![\"\"](\"http:\/\/www.bumc.bu.edu\/www\/Std_Images\/new2.gif\")